Celgene's lead product, Revlimid, a drug designed to treat multiple myeloma and a few other cancer types, has been benefiting from longer duration of use, strong pricing power, and high multiple myeloma market share.
CTLA - 4 blockade has mostly been used in melanoma, but also has been shown to be effective in prostate cancer, ovarian cancer, renal cancer, and a fewothertypes.